The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | Comparing ABVD, AVD & CHOP chemotherapy regimens in older patients with classical HL
Ninja Övergaard, PhD, Uppsala University, Uppsala, Sweden, describes the findings of a retrospective population and registry-based study that evaluated different chemotherapy regimens used to treat older patients with classical Hodgkin lymphoma (cHL). The study compared three main regimens: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), AVD (doxorubicin, vinblastine, dacarbazine), and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). No significant differences in overall survival (OS) were observed between the ABVD and AVD groups, while both were superior to CHOP. These findings indicate that the bleomycin component of ABVD treatment regimens can be omitted to reduce toxicity while maintaining efficacy. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
